Proteinuric diseases with sodium retention: Is plasmin the link?

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 1, 2012, Pages 117-124

  Svenningsen, Per ^a   Skøtt, Ole ^a   Jensen, Boye L ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Diabetes nephropathy; Epithelial sodium channel; Nephrotic syndrome; Pre eclampsia; Proteinuria; Sodium retention

Indexed keywords

ALDOSTERONE; AMILORIDE; ARGIPRESSIN; CAMOSTAT; EPITHELIAL SODIUM CHANNEL; FUROSEMIDE; NATRIURETIC FACTOR; NORADRENALIN; PLASMIN; PLASMINOGEN; PROSTASIN; PUROMYCIN AMINONUCLEOSIDE; RENIN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SPIRONOLACTONE;

ADRENERGIC SYSTEM; ALDOSTERONE BLOOD LEVEL; ARTICLE; DIABETIC NEPHROPATHY; EDEMA; ENZYME ACTIVATION; ENZYME BLOOD LEVEL; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY COLLECTING TUBULE; KIDNEY INJURY; KIDNEY TUBULE ABSORPTION; MICROALBUMINURIA; NEPHROTIC SYNDROME; NONHUMAN; NORADRENALIN BLOOD LEVEL; PATCH CLAMP; PREECLAMPSIA; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM ABSORPTION; SODIUM RETENTION; SODIUM TRANSPORT; SODIUM URINE LEVEL; WATER RETENTION;

ANIMALS; EPITHELIAL SODIUM CHANNEL; FIBRINOLYSIN; HUMANS; HYPERTENSION; KIDNEY TUBULES; NATRIURESIS; NEPHROTIC SYNDROME; PLASMINOGEN; PROTEINURIA; SODIUM CHLORIDE, DIETARY; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; WATER-ELECTROLYTE IMBALANCE;

EID: 84855172110     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05524.x     Document Type: Article

References (95)

1. Palmer BF, Alpern RJ, Selden DW, Giebisch G. Physiology and pathophysiology of sodium retention. In: Selden DW, Giebisch G (eds). The Kidney: Physiology and Pathophysiology. Lippincott Williams & Wilkins, New York, 2000; Ch. 54.
2. Geers AB, Koomans HA, Boer P, Dorhout Mees EJ. Plasma and blood volumes in patients with the nephrotic syndrome. Nephron 1984; 38: 170-3.
3. Dorhout Mees EJ, Geers AB, Koomans HA. Blood volume and sodium retention in the nephrotic syndrome: a controversial pathophysiological concept. Nephron 1984; 36: 201-11.
4. Usberti M, Federico S, Meccariello S et al. Role of plasma vasopressin in the impairment of water excretion in nephrotic syndrome. Kidney Int. 1984; 25: 422-9.
5. Walle JGV, Donckerwolcke ROMG. Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolaemic symptoms. Lancet 1995; 346: 148-52.
6. Ichikawa I, Rennke HG, Hoyer JR et al. Role for intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome. J. Clin. Invest. 1983; 71: 91-103.
7. Geers AB, Koomans HA, Roos JC, Boer P, Dorhout Mees EJ. Functional relationships in the nephrotic syndrome. Kidney Int. 1984; 26: 324-30.
8. Shapiro MD, Hasbargen J, Hensen J, Schrier RW. Role of aldosterone in the sodium retention of patients with nephrotic syndrome. Am. J. Nephrol. 1990; 10: 44-8.
9. Brown EA, Markandu ND, Sagnella GA, Jones BE, MacGregor GA. Lack of effect of captopril on the sodium retention of the nephrotic syndrome. Nephron 1984; 37: 43-8.
10. Brown EA, Markandu ND, Sagnella GA, Squires M, Jones BE, MacGregor GA. Evidence that some mechanism other than the renin system causes sodium retention in nephrotic syndrome. Lancet 1982; 2: 1237-40.
11. Svenningsen P, Bistrup C, Friis UG et al. Plasmin in nephrotic urine activates the epithelial sodium channel. J. Am. Soc. Nephrol. 2009; 20: 299-310.
12. Audige A, Yu ZR, Frey BM, Uehlinger DE, Frey FJ, Vogt B. Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome. Clin. Sci. (Lond) 2003; 104: 389-95.
13. Kim SW, Wang W, Nielsen J et al. Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats. Am. J. Physiol. Renal Physiol. 2004; 286: F922-35.
14. Sagae Y, Matsumoto Y, Unno K. Renin-sodium profile in experimental nephrosis induced by puromycin aminonucleoside. J. Pharmacobiodyn. 1983; 6: 475-80.
15. Lourdel S, Loffing J, Favre G et al. Hyperaldosteronemia and activation of the epithelial sodium channel are not required for sodium retention in puromycin-induced nephrosis. J. Am. Soc. Nephrol. 2005; 16: 3642-50.
16. de Seigneux S, Kim SW, Hemmingsen SC, Frokiaer J, Nielsen S. Increased expression but not targeting of ENaC in adrenalectomized rats with PAN-induced nephrotic syndrome. Am. J. Physiol. Renal Physiol. 2006; 291: F208-17.
17. Vogt B, Favre H. Na+, K(+)-ATPase activity and hormones in single nephron segments from nephrotic rats. Clin. Sci. (Lond) 1991; 80: 599-604.
18. Pedraza-Chaverri J, Cruz C, Ibarra-Rubio ME et al. Pathophysiology of experimental nephrotic syndrome induced by puromycin aminonucleoside in rats. I. The role of proteinuria, hypoproteinemia, and renin-angiotensin-aldosterone system on sodium retention. Rev. Invest. Clin. 1990; 42: 29-38.
19. Deschenes G, Wittner M, Stefano A, Jounier S, Doucet A. Collecting duct is a site of sodium retention in PAN nephrosis: a rationale for amiloride therapy. J. Am. Soc. Nephrol. 2001; 12: 598-601.
20. Kim SW, De Seigneux S, Sassen MC et al. Increased apical targeting of renal ENaC subunits and decreased expression of 11{beta}HSD2 in HgCl2-induced nephrotic syndrome in rats. Am. J. Physiol. Renal Physiol. 2005; 290: F674-87.
21. Vogt B, Dick B, Marti HP, Frey FJ, Frey BM. Reduced 11β-hydroxysteroid dehydrogenase activity in experimental nephrotic syndrome. Nephrol. Dial. Trans. 2002; 17: 753-8.
22. Kerstens MN, Buter H, Navis GJ, Dullaart RPF. 11b-hydroxysteroid dehydrogenase activity in proteinuric patients and the effect of angiotensin-II receptor blockade. Eur. J. Clin. Invest. 2002; 32: 513-18.
23. Bistrup C, Thiesson HC, Jensen BL, Skott O. Reduced activity of 11beta-hydroxysteroid dehydrogenase type 2 is not responsible for sodium retention in nephrotic rats. Acta Physiol. Scand. 2005; 184: 161-9.
24. Pedersen EB, Danielsen H, Madsen M, Jensen T. Defective renal water excretion in nephrotic syndrome: the relationship between renal water excretion and kidney function, arginine vasopressin, angiotensin II and aldosterone in plasma before and after oral water loading. Eur. J. Clin. Invest. 1985; 15: 24-9.
25. Sala C, Bedogna V, Gammaro L, Valvo E, Del Bo A, Morganti A. Central role of vasopressin in sodium/water retention in hypo- and hypervolemic nephrotic patients: a unifying hypothesis. J. Nephrol. 2004; 17: 653-7.
26. Deschenes G, Doucet A. Collecting duct (Na+/K+)-ATPase activity is correlated with urinary sodium excretion in rat nephrotic syndromes. J. Am. Soc. Nephrol. 2000; 11: 604-15.
27. Chandra M, Hoyer JR, Lewy JE. Renal function in rats with unilateral proteinuria produced by renal perfusion with aminonucleoside. Pediatr. Res. 1981; 15: 340-4.
28. Yu Z, Schumacher M, Frey BM, Frey FJ, Vogt B. Regulation of epithelial sodium channel in puromycin aminonucleoside-induced unilateral experimental nephrotic syndrome in normal and analbuminemic Nagase rats. Nephron Physiol. 2005; 101: 51-62.
29. Woolf AS, Lyon TL, Hoffbrand BI, Cohen SL, Moult PJ. Effects of physiological infusion of atrial natriuretic factor on healthy subjects and patients with the nephrotic syndrome. Nephron 1989; 52: 244-50.
30. Pedersen EB, Danielsen H, Eiskjaer H, Jespersen B, Sorensen SS. Increased atrial natriuretic peptide in the nephrotic syndrome Relationship to the renal function and the renin-angiotensin-aldosterone system. Scand. J. Clin. Lab. Invest. 1988; 48: 141-7.
31. Jespersen B, Eiskjaer H, Mogensen CE, Sorensen SS, Pedersen EB. Reduced natriuretic effect of atrial natriuretic peptide in nephrotic syndrome: a possible role of decreased cyclic guanosine monophosphate. Nephron 1995; 71: 44-53.
32. Perico N, Delaini F, Lupini C, Remuzzi G. Renal response to atrial peptides is reduced in experimental nephrosis. Am. J. Physiol. 1987; 252: F654-60.
33. Zietse R, Schalekamp MA. Effect of synthetic human atrial natriuretic peptide (102-126) in nephrotic syndrome. Kidney Int. 1988; 34: 717-24.
34. Tulassay T, Rascher W, Lang RE, Seyberth HW, Scharer K. Atrial natriuretic peptide and other vasoactive hormones in nephrotic syndrome. Kidney Int. 1987; 31: 1391-5.
35. Polzin D, Kaminski HJ, Kastner C et al. Decreased renal corin expression contributes to sodium retention in proteinuric kidney diseases. Kidney Int. 2010; 78: 650-9.
36. Keeler R. Chemical medullectomy does not prevent sodium retention in nephrotic rats. Miner. Electrolyte Metab. 1989; 15: 241-5.
37. Rahman SN, Abraham WT, Van Putten VJ, Hasbargen JA, Schrier RW. Increased norepinephrine secretion in patients with the nephrotic syndrome and normal glomerular filtration rates: evidence for primary sympathetic activation. Am. J. Nephrol. 1993; 13: 266-70.
38. Geers AB, Koomans HA, Dorhout Mees EJ. Effect of changes in posture on circulatory homeostasis in patients with the nephrotic syndrome. Clin. Physiol. 1986; 6: 63-75.
39. DiBona GF, Sawin LL, Jones SY. Characteristics of renal sympathetic nerve activity in sodium-retaining disorders. Am. J. Physiol. 1996; 271: R295-302.
40. DiBona GF, Herman PJ, Sawin LL. Neural control of renal function in edema-forming states. Am. J. Physiol. 1988; 254: R1017-24.
41. Koepke JP, DiBona GF. Blunted natriuresis to atrial natriuretic peptide in chronic sodium-retaining disorders. Am. J. Physiol. 1987; 252: F865-71.
42. Firth JD, Raine AE, Ledingham JG. Abnormal sodium handling occurs in the isolated perfused kidney of the nephrotic rat. Clin. Sci. (Lond.) 1989; 76: 387-95.
43. Shapiro MD, Nicholls KM, Groves BM, Schrier RW. Role of glomerular filtration rate in the impaired sodium and water excretion of patients with the nephrotic syndrome. Am. J. Kidney Dis. 1986; 8: 81-7.
44. Grausz H, Lieberman R, Earley LE. Effect of plasma albumin on sodium reabsorption in patients with nephrotic syndrome. Kidney Int. 1972; 1: 47-54.
45. Bernard DB, Alexander EA, Couser WG, Levinsky NG. Renal sodium retention during volume expansion in experimental nephrotic syndrome. Kidney Int. 1978; 14: 478-85.
46. Lourdel S, Zecevic M, Marc Paulais M et al. ENaC activation in experimental nephrotic syndrome. J. Am. Soc. Nephrol. 2001; 12: 138A.
47. Feraille E, Vogt B, Rousselot M et al. Mechanism of enhanced Na-K-ATPase activity in cortical collecting duct from rats with nephrotic syndrome. J. Clin. Invest. 1993; 91: 1295-300.
48. Guigonis V, Nathanson S, Doucet A, Deschenes G. Amiloride potentiates edema removal by furosemide in nephritic children. J. Am. Soc. Nephrol. 2001; 12: 135A.
49. Canessa CM, Schild L, Buell G et al. Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits. Nature 1994; 367: 463-7.
50. Canessa CM, Merillat AM, Rossier BC. Membrane topology of the epithelial sodium channel in intact cells. Am. J. Physiol. Cell Physiol. 1994; 267: C1682-90.
51. Frindt G, Palmer LG. Na channels in the rat connecting tubule. Am. J. Physiol. Renal Physiol. 2004; 286: F669-74.
52. Loffing J, Pietri L, Aregger F et al. Differential subcellular localization of ENaC subunits in mouse kidney in response to high- and low-Na diets. Am. J. Physiol. Renal Physiol. 2000; 279: F252-8.
53. Vallet V, Chraibi A, Gaeggeler HP, Horisberger JD, Rossier BC. An epithelial serine protease activates the amiloride-sensitive sodium channel. Nature 1997; 389: 607-10.
54. Vuagniaux G, Vallet V, Jaeger NF, Hummler E, Rossier BC. Synergistic activation of ENaC by three membrane-bound channel-activating serine proteases (mCAP1, mCAP2, and mCAP3) and serum- and glucocorticoid-regulated kinase (Sgk1) in Xenopus Oocytes. J. Gen. Physiol. 2002; 120: 191-201.
55. Chen LM, Skinner ML, Kauffman SW et al. Prostasin is a glycosylphosphatidylinositol-anchored active serine protease. J. Biol. Chem. 2001; 276: 21434-42.
56. Yu JX, Chao L, Chao J. Prostasin is a novel human serine proteinase from seminal fluid Purification, tissue distribution, and localization in prostate gland. J. Biol. Chem. 1994; 269: 18843-8.
57. Steensgaard M, Svenningsen P, Tinning AR et al. Apical serine protease activity is necessary for assembly of a high-resistance renal collecting duct epithelium. Acta. Physiol. (Oxf) 2010; 200: 347-59.
58. Svenningsen P, Uhrenholt TR, Palarasah Y, Skjodt K, Jensen BL, Skott O. Prostasin-dependent activation of epithelial Na+ channels by low plasmin concentrations. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009; 297: R1733-41.
59. Caldwell RA, Boucher RC, Stutts MJ. Serine protease activation of near-silent epithelial Na+ channels. Am. J. Physiol. Cell Physiol. 2004; 286: C190-4.
60. Caldwell RA, Boucher RC, Stutts MJ. Neutrophil elastase activates near-silent epithelial Na+ channels and increases airway epithelial Na+ transport. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005; 288: L813-19.
61. Chraibi A, Vallet V, Firsov D, Hess SK, Horisberger JD. Protease modulation of the activity of the epithelial sodium channel expressed in Xenopus oocytes. J. Gen. Physiol. 1998; 111: 127-38.
62. Passero CJ, Mueller GM, Rondon-Berrios H, Tofovic SP, Hughey RP, Kleyman TR. Plasmin activates epithelial Na+ channels by cleaving the gamma subunit. J. Biol. Chem. 2008; 283: 36586-91.
63. Kleyman TR, Carattino MD, Hughey RP. ENaC at the cutting edge: regulation of epithelial sodium channels by proteases. J Biol Chem 2009; 284: 20447-51.
64. Nakayama K. Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem. J. 1997; 327 (Pt 3): 625-35.
65. Hughey RP, Bruns JB, Kinlough CL et al. Epithelial sodium channels are activated by furin-dependent proteolysis. J. Biol. Chem. 2004; 279: 18111-14.
66. Hughey RP, Mueller GM, Bruns JB et al. Maturation of the epithelial Na+ channel involves proteolytic processing of the alpha- and gamma-subunits. J. Biol. Chem. 2003; 278: 37073-82.
67. Bruns JB, Carattino MD, Sheng S et al. Epithelial Na+ channels are fully activated by furin- and prostasin-dependent release of an inhibitory peptide from the gamma subunit. J. Biol. Chem. 2007; 282: 6153-60.
68. Carattino MD, Sheng S, Bruns JB, Pilewski JM, Hughey RP, Kleyman TR. The epithelial Na+ channel is inhibited by a peptide derived from proteolytic processing of its alpha subunit. J. Biol. Chem. 2006; 281: 18901-7.
69. Sheng S, Carattino MD, Bruns JB, Hughey RP, Kleyman TR. Furin cleavage activates the epithelial Na+ channels by relieving Na+ self-inhibition. Am. J. Physiol. Cell Physiol. 2006; 290: F1488-96.
70. Hughey RP, Bruns JB, Kinlough CL, Kleyman TR. Distinct pools of epithelial sodium channels are expressed at the plasma membrane. J. Biol. Chem. 2004; 279: 48491-4.
71. Naray-Fejes-Toth A, Canessa C, Cleaveland ES, Aldrich G, Fejes-Toth G. sgk is an aldosterone-induced kinase in the renal collecting duct Effects on epithelial na+ channels. J. Biol. Chem. 1999; 274: 16973-8.
72. Shipway A, Danahay H, Williams JA, Tully DC, Backes BJ, Harris JL. Biochemical characterization of prostasin, a channel activating protease. Biochem. Biophys. Res. Commun. 2004; 324: 953-63.
73. Gadau J, Peters H, Kastner C et al. Mechanisms of tubular volume retention in immune-mediated glomerulonephritis. Kidney Int. 2009; 75: 699-710.
74. Frindt G, Ergonul Z, Palmer LG. Surface expression of epithelial Na channel protein in rat kidney. J. Gen. Physiol. 2008; 131: 617-27.
75. Masilamani S, Kim GH, Mitchell C, Wade JB, Knepper MA. Aldosterone-mediated regulation of ENaC alpha, beta, and gamma subunit proteins in rat kidney. J. Clin. Invest. 1999; 104: R19-23.
76. Kastner C, Pohl M, Sendeski M et al. Effects of receptor-mediated endocytosis and tubular protein composition on volume retention in experimental glomerulonephritis. Am. J. Physiol. Renal. Physiol. 2009; 296: F902-11.
77. Raum D, Marcus D, Alper CA, Levey R, Taylor PD, Starzl TE. Synthesis of human plasminogen by the liver. Science 1980; 208: 1036-7.
78. Zhang L, Seiffert D, Fowler BJ et al. Plasminogen has a broad extrahepatic distribution. Thromb. Haemost. 2002; 87: 493-501.
79. Vaziri ND, Gonzales EC, Shayestehfar B, Barton CH. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome. J. Lab. Clin. Med. 1994; 124: 118-24.
80. Piedagnel R, Tiger Y, Lelongt B, Ronco PM. Urokinase (u-PA) is produced by collecting duct principal cells and is post-transcriptionally regulated by SV40 large-T, arginine vasopressin, and epidermal growth factor. J. Cell. Physiol. 2006; 206: 394-401.
81. Wagner SN, Atkinson MJ, Wagner C, Hofler H, Schmitt M, Wilhelm O. Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney. Histochem. Cell Biol. 1996; 105: 53-60.
82. Vassalli JD, Belin D. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett. 1987; 214: 187-91.
83. Moghrabi S, Houillier P, Picard N et al. Tissue kallikrein permits early renal adaptation to potassium load. Proc. Natl. Acad. Sci. USA 2010; 107: 13526-31.
84. Margolius HS, Chao J. Amiloride inhibits mammalian renal kallikrein and a kallikrein-like enzyme from toad bladder and skin. J. Clin. Invest. 1980; 65: 1343-50.
85. Azizi M, Boutouyrie P, Bissery A et al. Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. J. Clin. Invest. 2005; 115: 780-7.
86. Carattino MD, Hughey RP, Kleyman TR. Proteolytic processing of the epithelial sodium channel gamma subunit has a dominant role in channel activation. J Biol Chem. 2008; 283: 25290-5.
87. Sharom FJ, Lehto MT. Glycosylphosphatidylinositol-anchored proteins: structure, function, and cleavage by phosphatidylinositol-specific phospholipase C. Biochem. Cell Biol. 2002; 80: 535-49.
88. Hill WG, An B, Johnson JP. Endogenously expressed epithelial sodium channel is present in lipid rafts in A6 cells. J. Biol. Chem. 2002; 277: 33541-4.
89. Vallet V, Pfister C, Loffing J, Rossier BC. Cell-surface expression of the channel activating protease xCAP-1 is required for activation of ENaC in the Xenopus oocyte. J. Am. Soc. Nephrol. 2002; 13: 588-94.
90. Vuagniaux G, Vallet V, Jaeger NF et al. Activation of the amiloride-sensitive epithelial sodium channel by the serine protease mCAP1 expressed in a mouse cortical collecting duct cell line. J. Am. Soc. Nephrol. 2000; 11: 828-34.
91. Chen HF, Nakabayashi M, Satoh K, Sakamoto S. Urinary fibrinolysis in toxemia of pregnancy. Acta Obstet. Gynecol. Scand. 1980; 59: 499-504.
92. Coote K, Atherton-Watson H, Sugar R et al. Camostat attenuates airway ENaC function in vivo through the inhibition of a Channel Activating Protease. J. Pharmacol. Exp. Ther. 2009; 329: 764-74.
93. Maekawa A, Kakizoe Y, Miyoshi T et al. Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension. J. Hypertens. 2009; 27: 181-9.
94. Ikeda Y, Ito H, Hashimoto K. Effect of camostat mesilate on urinary protein excretion in three patients with advanced diabetic nephropathy. J. Diabetes Complications 1999; 13: 56-8.
95. Tully DC, Vidal A, Chatterjee AK et al. Discovery of inhibitors of the channel-activating protease prostasin (CAP1/PRSS8) utilizing structure-based design. Bioorg. Med. Chem. Lett. 2008; 18: 5895-9.